Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma

ClinicalTrials.gov ID: NCT01144455

Public ClinicalTrials.gov record NCT01144455. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine whether Gemcitabine versus Gemcitabine and TH-302 are effective in the treatment of subjects with first-line metastatic pancreatic adenocarcinoma.

Study identification

NCT ID
NCT01144455
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
ImmunoGenesis
Industry
Enrollment
214 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2010
Primary completion
Aug 31, 2013
Completion
Nov 30, 2014
Last update posted
May 10, 2025

2010 – 2014

United States locations

U.S. sites
59
U.S. states
29
U.S. cities
55
Facility City State ZIP Site status
Birmingham Hematology and Oncology Associates, LLC Birmingham Alabama 35223 —
Mayo Clinic Arizona Scottsdale Arizona 85259 —
Arizona Oncology Associates, PC - HOPE Tucson Arizona 85704 —
University of Arizona Tucson Arizona 85724 —
Saint Edward Mercy Medical Center Fort Smith Arkansas 72917 —
Disney Family Cancer Center Burbank California 91505 —
Scripps Clinical Research Services La Jolla California 92037 —
UCLA Medical Center Los Angeles California 90095 —
Palo Alto Medical Foundation Mountain View California 94040 —
Los Palos Oncology and Hematology Salinas California 93901 —
Sharp Memorial Hospital San Diego California 92123 —
California Pacific Medical Center San Francisco California 94115 —
Rocky Mountain Cancer Centers Denver Colorado 80218 —
Hematology Oncology Associates, PC Stamford Connecticut 06902 —
Florida Cancer Institute - New Hope New Port Richey Florida 34655 —
Ocala Oncology Center Ocala Florida 34471 —
Martin Memorial Cancer Center Stuart Florida 34994 —
Atlanta Cancer Care Atlanta Georgia 30342 —
Loyola University Medical Center Maywood Illinois 60153 —
Carle Cancer Center Urbana Illinois 61901 —
Indiana University Melvin and Bren Simon Cancer Indianapolis Indiana 46202 —
Purchase Cancer Group Paducah Kentucky 42002 —
Medical Oncology Baton Rouge Louisiana 70809 —
Ochsner Cancer Institute New Orleans Louisiana 70121 —
LSU Health Sciences Center - Feist Weiller Cancer Center Shreveport Louisiana 71130 —
Massachusetts General Hospital Boston Massachusetts 02114 —
University of Massachusetts Medical Center Worcester Massachusetts 01655 —
Virgina Piper Cancer Institute Minneapolis Minnesota 55407 —
Mayo Clinic Rochester Rochester Minnesota 55905 —
Hematology and Oncology Associates at BridgePoint Tupelo Mississippi 38801 —
Missouri Cancer Associates Columbia Missouri 65201 —
Montana Cancer Institute Foundation Missoula Montana 59802 —
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89169 —
Roswell Park Cancer Institute Buffalo New York 14263 —
New York Oncology Hematology, P.C. Hudson New York 12534 —
Cancer Care of Western North Carolina, PA Asheville North Carolina 28801 —
Alamance Oncology Hematolgy Associates Burlington North Carolina 27599 —
Duke University Medical Center Durham North Carolina 27710 —
Carolina Oncology Specialists, PA Hickory North Carolina 28602 —
Emerywood Hematology and Oncology High Point North Carolina 27262 —
Signal Point Clinical Research Center Middletown Ohio 45042 —
Kaiser Permanente Northwest Region Oncology Hematology Portland Oregon 97227 —
Northwest Cancer Specialists, P.C. Portland Oregon 97227 —
Greater Philadelphia Cancer and Hematology Specialists, P.C. Philadelphia Pennsylvania 19114 —
Allegheny General Hospital Pittsburgh Pennsylvania 15212 —
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15232 —
Institute for Translational Oncology Research (ITOR) Greenville South Carolina 29605 —
Vanderbilt University Medical Center, Div. of Medical Oncology Nashville Tennessee 37232 —
Texas Oncology-Beaumont, Mamie McFaddin Ward Cancer Center Beaumont Texas 77702 —
Texas Oncology-Dallas Presbyterian Hospital Dallas Texas 75231 —
University of Texas Southwestern Medical Center at Dallas Dallas Texas 75390 —
Texas Oncology- Fort Worth - 12th Avenue Fort Worth Texas 76104 —
Texas Oncology-Seton Williamson Round Rock Texas 78665 —
Texas Oncology-Sherman Sherman Texas 75090 —
Texas Oncology-Wichita Falls Texoma Cancer Center Wichita Falls Texas 76310 —
Fairfax Northern Virginia Hematology Oncology, PC Fairfax Virginia 22031 —
Providence Everett Regional Medical Center, Cancer Research Dept. Everett Washington 98201 —
Columbia Basin Hematology and Oncology0 Kennewick Washington 99336 —
University of Wisconsin Madison Wisconsin 53792 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01144455, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 10, 2025 · Synced Sep 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01144455 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →